GLCACS 17th Annual Conference - Latest Breakthrough Technologies

---

• Time & Location:

May 4th 2013 (Saturday) 9:00-20:00

Baxter Healthcare Corporation, Technology Park

25212 W. IL Rte 120, Round Lake IL 60073

• Eevent Agenda:

9:00-9:30 Registration/ Poster Mounting

9:30-9:40 Welcome

9:40-10:25 Dr. Katharine Qiu

Sr. Director, Medical Products, R&D, Baxter Healthcare Corp.

10:25-11:10 Mr. Guy Lewis

Strategic Marketing Director, Honeywell UOP

11:10-11:30 GLCACS Announcement and Break

11:30-13:00 Poster Presentation Competition

13:00-14:30 Poster Session, Career Fair and Lunch Break

14:30-15:15 Dr. Harold Kung

Professor of Chemical and Biological Engineering,

Northwestern University

15:15-16:00 Dr. Yingming Zhao

Professor of the Ben May Department for Cancer Research,

University of Chicagok

16:00-16:45 Dr. Yihong Qiu

Sr. Research Fellow, AbbVie Inc.n I

16:45-17:00 Break and Poster Competition Ballot Casting

17:00-17:15 Poster Awards and Closing Remarkark

18:00-20:00 Dinner Reception

---

• Guest Speakers:

A Career with Higher Purpose- Saving and Sustaining Lives Worldwide - Dr. Katharine Qiu

Dr. Katharine Qiu

Sr. Director, Medical Products, R&D, Baxter Healthcare Corp

Abstract

If you are contemplating a career of higher purpose- saving and sustaining lives, you can find satisfaction at Baxter. If you have a desire to learn and grow – delivering innovative products and services to patients in the established and developing markets, you can find opportunities at Baxter. Whether you’re interested in medical devices, pharmaceuticals or biotechnology – or all three – Baxter offers an exciting

environment, global R&D footprint and diverse culture to help you explore and find the path that’s right for you.

Biography

Katharine Qiu is Senior Director, Technology Resources, Medical Products in Baxter. Katharine joined Baxter in 2007 as Director, Research & Development in Renal Division. Prior to joining Baxter, Katharine held several technical and program management positions responsible for new product development and global launch at Abbott Diagnostic Division, Abbott Laboratories. Katharine was an Arthritis Foundation Postdoctoral Fellow at Northwestern University prior to joining Abbott. Katharine

co-leads the communication committee of Building Women Leaders at Baxter and serves on the Board of Directors for the Allotrope Foundation. Katharine received her B.S. in Biochemical Engineering from East China University of Technology in China and her Ph.D. in Chemistry from Colorado State University in USA.

Innovations Enabling the Shale Revolution - Mr. Guy Lewis

Mr. Guy Lewis

Strategic Marketing Director, Gas Processing and Hydrogen, Honeywell UOP

Abstract

New sources of energy will be required to meet increasing global and regional demands. This is particularly true for natural gas which has proven to be a cleaner burning and flexible fuel. Fortunately, the shale revolution has enabled a transformation of the energy mix of the United States. The revolution is about to spread to other parts of the world.

There were a few key technological breakthroughs that enabled this revolution. The foundation was set by the combination of hydraulic fracturing, horizontal drilling, and 3-D microseismic imaging. Business model innovations were just as important as the innovations in technology. Additional innovations were required to repeat the initial success of the Barnett gas shale for other resources because the geology and gas composition of each resource is different. This won’t be any different as shale resources are developed elsewhere. Each new source of supply brings challenges for drilling, production, gas treating, and distribution infrastructure. This is particularly true of shale gas as composition is likely to vary significantly from one development area to another. Being able to deploy a diverse portfolio of technologies and adapting this portfolio to each resource is a key to successfully monetizing unconventional resources anywhere in the world.

The role of innovation is not over. Operators need solutions that provide assurance they can monetize new resources. Governments, stakeholders and end-users are looking for assurance that the gas and oil compositional changes from new developments will not have an adverse impact on their delivery infrastructure and on their customers’ end-use applications. Environmental groups and communities are

looking for assurance that their quality of life will not be adversely impacted by resource development.

This presentation will review the innovations below ground and above ground that have enabled this revolution and highlight priorities for additional innovations to turn remaining challenges into opportunity and enable unconventional resource owners to successfully monetize their assets.

Biography

Guy Lewis serves as Strategic Marketing Director for the Gas Processing and Hydrogen business of Honeywell’s UOP. Honeywell’s UOP is a leading international supplier of process technology, catalysts, engineered systems, and technical and engineering services to the petroleum refining, petrochemical, chemical, and gas processing and hydrogen industries. The UOP business is part of the Performance Materials and Technologies strategic business group of Honeywell International.

Prior to joining Honeywell’s UOP in 2012, Guy served as Executive Director for Strategic Growth Initiatives at Gas Technology Institute (GTI), developing new offers and positioning GTI businesses for entry in Europe and China, and as Managing Director for Unconventional Gas, leading the company’s global technology, economic, and environmental efforts in this critical area. Prior to joining GTI in 2007, Guy held a number of positions of increasing responsibility at BP during his nearly 30 year tenure,

including Vice President for U.S. Retail Strategy and Planning, Vice President for Commercial Business Solutions, and Vice President for U.S. Marketing Fuel Supply.

Guy holds an M.B.A. from the University of Chicago and a bachelor’s degree in chemical engineering from Northwestern University.

Li Ion Battery – Moving Forward - Dr. Harold Kung

Dr. Harold Kung

Professor., Chemical and Biological Engineering Department, Northwestern University.

Abstract

Li ion batteries are the preferred rechargeable source of electricity for many mobile devices. Because of its high energy density, it is also the battery for electric vehicles and hybrids. However, future devices demand substantially higher performance than current generation of batteries can provide. Here we discuss areas of improvement needed and advances in some of these areas.

Biography

Harold H. Kung is Professor of Chemical and Biological Engineering at Northwestern University. He received his B.S. degree in chemical engineering from the University of Wisconsin, Madison, and his Ph.D. degree in chemistry from Northwestern University. His research interest includes heterogeneous catalysis, energy storage, synthesis of nanostructured materials, global energy supply and consumption, and sustainability. He authored “Transition Metal Oxides: Surface Chemistry and Catalysis,” and is recipient of the Gabor A. Somorjai Award of the American Chemical society, the P.H. Emmett Award and the Robert Burwell Lectureship Award (North American Catalysis Society), the Herman Pines Award (Chicago Catalysis Club), Catalysis Society of South Africa Eminent Visitor Award, Cross-Canada Lectureship of the Catalysis Division of the Chemical Institute of Canada, and the Ernest Thiele Award (AIChE Chicago Section). He is named the 2009 Northwestern University Dorothy Ann and Clarence L. Ver Steeg Distinguished Research Fellow, a fellow of American Association for the Advancement of Science, and an editor of Applied Catalysis A: General since 1996. He has published over 250 technical papers.

New Lysine Acylation Pathways, New Histone Marks, and Their Regulatory Enzymes - Dr. Yingming Zhao

Dr. Yingming Zhao

Professor, Ben May Department for Cancer Research, The University of Chicago

Abstract

Dynamic changes in the lysine post-translational modification (PTM) pathways are crucial for organismal development as well as cell development, differentiation and function. Dysregulation of these pathways have been linked with abnormal physiological conditions and almost all diseases. Histones are model proteins for PTM studies and histone PTMs contribute epigenomic programs and cellular physiology.

Numerous PTMs have been identified within histones resulting from collective efforts from research community, and much is known about the functions of these modifications. Despite the progress, it remains unknown if additional histone marks exist in cells. In this presentation, we will discuss our recent identification of six types of novel histone PTM using an integrated approach involving in vitro propionylation, peptide fractionation, and HPLC/MS/MS in LTQ Orbitrap Velos mass spectrometry.

These new histone PTMs are lysine propionylation, lysine butyrylation, lysine malonylation, lysine succinylation, lysine crotonylation and tyrosine hydroxylation. We identified more than 120 new histone PTM sites, which more than doubles the number of previously described histone marks that were discovered by the whole research community over the past few decades. To validate these new PTMs biologically, we carried out preliminary characterization and functional studies of the five lysine

modification pathways by identifying their regulatory enzymes, and studying their epigenetic functions and their possible roles in energy metabolism. Using the same mass spectrometry technology, we carried out the first few proteomics studies to identify the HDAC-regulated sub-proteomes. This analysis led to identifying 4,500 lysine-acetylation substrates, some of which are regulated by Sirt1 and HDAC6, two

HDAC enzymes with multiple disease implications. This result conclusively demonstrates the superior sensitivity of our HPLC/MS/MS system, which provides a powerful technology platform for discovery of new cellular pathways and for identifying disease- or enzyme-specific biomarkers.

Biography

Yingming Zhao received his Ph.D. degree from the Rockefeller University under Professor Brian Chait in 1997. He is currently a Professor in the Ben May Department for Cancer Research at the University of Chicago. His main research interests lie in developing and applying MS-based proteomics technologies to studying protein post-translational modifications (PTMs). His laboratory uses proteomics technologies in

combination with biochemistry, molecular biology, and cell biology, to decode PTM networks critical for human health that are not amenable to conventional approaches. He co-authored 108 peer reviewed papers and is a co-inventor of numerous patents. In the past several years, his laboratory has identified five types of novel lysine PTM pathways and discovered 121 novel histone marks, more histone marks than the whole research community identified in the past few decades.

Recent Trends and Career Opportunities within the Pharmaceutical Industry - Dr. Yihong Qiu

Dr. Yihong Qiu

Sr. Research Fellow, Oral Drug Products, Manufacturing Science and Technology

Biography

Dr. Yihong Qiu is currently Volwiler Senior Research Fellow at AbbVie. He started his career at Abbott Laboratories in 1992 and has since accumulated in-depth knowledge and extensive experience that encompass various phases of drug product development, including preformulation, biopharmaceutics, drug delivery, product/process design, development, scale-up and optimization, manufacturing trouble-shooting, intellectual property (IP) and regulatory registration for new drugs and marketed products. He also plays a key role in IP strategy, business development and product life cycle management. During his tenure at Abbott, he developed patented drug delivery technologies and commercial products with peak annual sales of over $ 1 billion.

Dr. Qiu is an elected fellow of the American Association of Pharmaceutical Scientists (AAPS) and a member of United States Pharmacopeia Expert Committee. He has more than 50 publications in journals and books, 30 patents granted or pending, and numerous conference presentations. He also received many awards including 2012 Scientific Governing Board Innovation Award. He contributes regularly to professional organizations and institutions, such as AAPS, Chinese Pharmaceutical Association (CPA), US Food and Drug Administration (FDA), and universities through presenting, lecturing, editing/refereeing publications, and organizing meetings. Dr. Qiu received a BS in Pharmacy, a MS. in Pharmaceutics from China Pharmaceutical University, and Ph.D. in Pharmaceutics from The University of Iowa.

Conference brochure